WO2007114838A1 - Amylin and amylin agonists for treating psychiatric diseases and disorders - Google Patents

Amylin and amylin agonists for treating psychiatric diseases and disorders Download PDF

Info

Publication number
WO2007114838A1
WO2007114838A1 PCT/US2006/038919 US2006038919W WO2007114838A1 WO 2007114838 A1 WO2007114838 A1 WO 2007114838A1 US 2006038919 W US2006038919 W US 2006038919W WO 2007114838 A1 WO2007114838 A1 WO 2007114838A1
Authority
WO
WIPO (PCT)
Prior art keywords
amylin
seq
xaa
disorder
hamylin
Prior art date
Application number
PCT/US2006/038919
Other languages
English (en)
French (fr)
Inventor
Kevin D. Laugero
Michael Hanley
Christine Mack
David G. Parkes
Andrew A. Young
Original Assignee
Amylin Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Application filed by Amylin Pharmaceuticals, Inc. filed Critical Amylin Pharmaceuticals, Inc.
Priority to AU2006341375A priority Critical patent/AU2006341375B2/en
Priority to CA002647568A priority patent/CA2647568A1/en
Priority to US12/295,259 priority patent/US20090181890A1/en
Priority to EP06816288A priority patent/EP2010208A1/en
Priority to KR1020087023804A priority patent/KR20080106950A/ko
Priority to PCT/US2006/038919 priority patent/WO2007114838A1/en
Priority to JP2009502755A priority patent/JP2009538824A/ja
Priority to MX2008012666A priority patent/MX2008012666A/es
Publication of WO2007114838A1 publication Critical patent/WO2007114838A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2006/038919 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders WO2007114838A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2006341375A AU2006341375B2 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders
CA002647568A CA2647568A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders
US12/295,259 US20090181890A1 (en) 2006-03-31 2006-10-04 Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
EP06816288A EP2010208A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders
KR1020087023804A KR20080106950A (ko) 2006-03-31 2006-10-04 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders
JP2009502755A JP2009538824A (ja) 2006-03-31 2006-10-04 精神疾患及び障害治療用アミリン及びアミリンアゴニスト
MX2008012666A MX2008012666A (es) 2006-03-31 2006-10-04 Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2006/012601 2006-03-31
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (1)

Publication Number Publication Date
WO2007114838A1 true WO2007114838A1 (en) 2007-10-11

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Country Status (7)

Country Link
EP (1) EP2010208A1 (ko)
JP (1) JP2009538824A (ko)
KR (1) KR20080106950A (ko)
AU (1) AU2006341375B2 (ko)
CA (1) CA2647568A1 (ko)
MX (1) MX2008012666A (ko)
WO (1) WO2007114838A1 (ko)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046852A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
WO2009046853A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of intermedin 47 peptide as a therapeutic agent
WO2009156473A1 (en) * 2008-06-25 2009-12-30 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
WO2011063414A1 (en) 2009-11-23 2011-05-26 Amylin Pharmaceuticals, Inc. Polypeptide conjugate
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
EP3927725A4 (en) * 2019-02-22 2023-06-14 Loyola Marymount University AMYLOID PEPTIDE VARIANTS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5686411A (en) * 1991-03-08 1997-11-11 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US20050197287A1 (en) * 2004-03-04 2005-09-08 Mack Christine M. Methods for affecting body composition
WO2005081619A2 (en) * 2003-11-20 2005-09-09 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2006105345A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Compositions and methods for the control, prevention, and treatment of obesity and eating disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE157010T1 (de) * 1991-05-24 1997-09-15 Amylin Pharmaceuticals Inc Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5686411A (en) * 1991-03-08 1997-11-11 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
WO2005081619A2 (en) * 2003-11-20 2005-09-09 Neuronova Ab Compounds and methods for increasing neurogenesis
US20050197287A1 (en) * 2004-03-04 2005-09-08 Mack Christine M. Methods for affecting body composition
WO2006105345A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BARON ET AL.: "Curr. Drug Targets Immune Endocr", METABOL. DISORD., vol. 2, 2002, pages 63 - 82
CHROUSOS ET AL., INT. J. OBES. RELAT. METAB. DISORD., vol. 24, 2000, pages S50 - S55
DALLMAN ET AL., HONNONES, BRAIN, AND BEHAVIOR, 2002, pages 571 - 631
DALLMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 11696 - 11701
HALFORD JASON C G ET AL: "THE PSYCHOPHARMACOLOGY OF APPETITE: TARGETS FOR POTENTIAL ANTI-OBESITY AGENTS", CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD., BUSSUM, NL, vol. 3, no. 4, December 2003 (2003-12-01), pages 283 - 310, XP009073953, ISSN: 1871-5249 *
KODA ET AL., LANCET, vol. 339, 1992, pages 1179 - 1180
KOOB, BIOL. PSYCHIATRY, vol. 46, 1999, pages 1167 - 1180
KOVACS ANNA-MARIA ET AL: "The effects of amylin on motivated behavior in rats", PHYSIOLOGY AND BEHAVIOR, vol. 60, no. 1, 1996, pages 183 - 186, XP002438529, ISSN: 0031-9384 *
MACK ET AL., DIABETES, vol. 52, no. 1, 2003, pages A389
MORLEY J E ET AL: "EFFECTS OF AMYLIN ON APPETITE REGULATION AND MEMORY", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, OTTAWA, ONT, CA, vol. 73, 1 July 1995 (1995-07-01), pages 1042 - 1046, XP002910219 *
RATNER ROBERT E ET AL: "Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes", DIABETES TECHNOLOGY AND THERAPEUTICS, MARY ANN LIEBERT, LARCHMONT, NY, US, vol. 4, no. 1, 2002, pages 51 - 61, XP009074054, ISSN: 1520-9156 *
See also references of EP2010208A1 *
YOUNG, CURR. OPIN. IN ENDOCRINOLOGY AND DIABETES, vol. 4, 1997, pages 282 - 290

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046852A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
WO2009046853A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of intermedin 47 peptide as a therapeutic agent
WO2009156473A1 (en) * 2008-06-25 2009-12-30 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
CN102076353A (zh) * 2008-06-25 2011-05-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー／エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
WO2011063414A1 (en) 2009-11-23 2011-05-26 Amylin Pharmaceuticals, Inc. Polypeptide conjugate
EP3028720A1 (en) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action
EP3305315A1 (en) 2010-09-28 2018-04-11 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
US9593154B2 (en) 2010-09-28 2017-03-14 Astrazeneca Pharmaceuticals Lp Engineered polypeptides having enhanced duration of action
EP3241558A2 (en) 2010-09-28 2017-11-08 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
US10087228B2 (en) 2010-09-28 2018-10-02 Aegerion Pharmaceuticals, Inc. Chimeric leptin polypeptide and method of using the same
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US9879063B2 (en) 2011-07-08 2018-01-30 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
EP3927725A4 (en) * 2019-02-22 2023-06-14 Loyola Marymount University AMYLOID PEPTIDE VARIANTS

Also Published As

Publication number Publication date
KR20080106950A (ko) 2008-12-09
MX2008012666A (es) 2008-10-13
EP2010208A1 (en) 2009-01-07
AU2006341375A1 (en) 2007-10-11
JP2009538824A (ja) 2009-11-12
AU2006341375B2 (en) 2013-03-21
AU2006341375A2 (en) 2009-09-24
CA2647568A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
US7671023B2 (en) Amylin agonist for treating depression, anxiety disorder and schizophrenia
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
ES2309108T3 (es) Tratamiento de enfermedades neurologicas y neuropsicologicas.
US7485620B2 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
US20130035294A1 (en) Neuromedin and FN-38 Peptides for Psychotic Diseases
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
US20070275877A1 (en) Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
CA3212248A1 (en) Improved methods of treating diseases resulting from a maladapted stress response

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06816288

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2006341375

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2647568

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020087023804

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012666

Country of ref document: MX

Ref document number: 2009502755

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200680054122.2

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2006341375

Country of ref document: AU

Date of ref document: 20061004

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006816288

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12295259

Country of ref document: US